Appclon Rises 5.83% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.17% compared to the previous day, showing strength, while Appclon, a related stock drawing attention, surged by 5.83% compared to the previous day. Appclon is known as the only domestic bio new drug development specialist among listed companies.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Appclon's quant financial score is 10.51 points, with higher growth and stability scores than the average of other stocks related to COVID-19 (diagnosis/treatment/vaccine development, etc.), but its quant financial ranking was only 27th out of 47 stocks. On the other hand, United Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the robo algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.